全球抗體療法市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

預計抗體療法市場將從 2025 年的 3,164.7 億美元成長到 2034 年的 1.0596 兆美元，2026 年至 2034 年的複合年成長率為 14.37%。

由於對標靶治療的需求不斷成長，全球抗體療法市場正經歷顯著成長。單株抗體廣泛應用於腫瘤學、自體免疫疾病和感染疾病領域。慢性病盛行率的上升和生物技術的進步正在推動市場擴張。

關鍵成長要素包括生物製劑產品線的擴張和研發投入的增加。製藥公司正在開發具有更高特異性和更低副作用的新一代抗體。醫療保健支出的成長和有利的報銷政策進一步刺激了需求。此外，抗體工程技術的進步也提高了治療效果。

展望未來，生物相似藥的研發和新型抗體製劑的出現可望為市場帶來強勁成長動力。新興市場生物製藥可及性的提高也將創造成長機會。各公司正致力於創新給藥方式和聯合治療，隨著精準醫療的進步，全球抗體療法市場預計將穩定成長。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章：全球抗體療法市場：依形式分類

• 市場分析、洞察與預測
• 單株抗體
• 多株抗體療法
• 雙特異性抗體
• 抗體片段
• 其他

第5章 全球抗體療法市場：依疾病領域分類

• 市場分析、洞察與預測
• 自體免疫疾病與發炎性疾病
• 腫瘤學
• 血液學
• 感染疾病
• 骨學
• 免疫學
• 神經病學
• 其他

第6章：全球抗體療法市場：依給藥途徑分類

• 市場分析、洞察與預測
• 靜脈注射
• 皮下注射

第7章：全球抗體療法市場：依來源分類

• 市場分析、洞察與預測
• 人類
• 人源化抗體
• 嵌合體
• 其他

第8章 全球抗體療法市場：依最終用戶分類

• 市場分析、洞察與預測
• 醫院
• 長期照護機構
• 其他

第9章 全球抗體療法市場：按地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第10章 競爭格局

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第11章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • F. Hoffmann-La Roche Ltd.（Switzerland）
  • AbbVie Inc.（US）
  • Johnson & Johnson（US）
  • Merck KGaA（Germany）
  • Bristol-Myers Squibb（US）
  • AstraZeneca（UK）
  • Sanofi（France）
  • Regeneron Pharmaceuticals, Inc.（US）
  • Novartis AG（Switzerland）
  • Amgen, Inc.（US）
  • Biogen Inc.（US）

The Antibody Therapeutics Market size is expected to reach USD 1059.60 Billion in 2034 from USD 316.47 Billion (2025) growing at a CAGR of 14.37% during 2026-2034.

The Global Antibody Therapeutics Market is witnessing substantial growth due to increasing demand for targeted treatments. Monoclonal antibodies are widely used in oncology, autoimmune diseases, and infectious diseases. Rising prevalence of chronic conditions and advancements in biotechnology are supporting market expansion.

Key growth drivers include expansion of biologics pipelines and increasing R&D investments. Pharmaceutical companies are developing next-generation antibodies with improved specificity and reduced side effects. Growing healthcare expenditure and favorable reimbursement policies are further boosting demand. Additionally, advancements in antibody engineering technologies are enhancing therapeutic efficacy.

Looking ahead, the market is expected to benefit from biosimilar development and novel antibody formats. Emerging markets improving access to biologic therapies will create growth opportunities. Companies are focusing on innovative delivery methods and combination therapies. As precision medicine continues to evolve, the Global Antibody Therapeutics Market is projected to grow steadily.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Format

• Monoclonal Antibody
• Polyclonal Antibody Therapy
• Bispecific Antibody
• Antibody Fragment
• Other

By Disease Areas

• Autoimmune & Inflammatory Diseases
• Oncology
• Hematology
• Infectious Diseases
• Osteology
• Immunology
• Neurology
• Other

By Route Of Administration

• Intravenous
• Subcutaneous

By Source

• Human
• Humanized
• Chimeric
• Other

By End User

• Hospitals
• Long-Term Care Facilities
• Other

COMPANIES PROFILED

• F HoffmannLa Roche Ltd Switzerland, AbbVie Inc US, Johnson Johnson US, Merck KGaA Germany, BristolMyers Squibb US, AstraZeneca UK, Sanofi France, Regeneron Pharmaceuticals, Inc US, Novartis AG Switzerland, Amgen, Inc US, Biogen Inc US
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL ANTIBODY THERAPEUTICS MARKET: BY FORMAT 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Format
• 4.2. Monoclonal Antibody Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Polyclonal Antibody Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Bispecific Antibody Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Antibody Fragment Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Other Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL ANTIBODY THERAPEUTICS MARKET: BY DISEASE AREAS 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Disease Areas
• 5.2. Autoimmune & Inflammatory Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Oncology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Hematology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Infectious Diseases Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Osteology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.7. Immunology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.8. Neurology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.9. Other Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL ANTIBODY THERAPEUTICS MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Route Of Administration
• 6.2. Intravenous Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Subcutaneous Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL ANTIBODY THERAPEUTICS MARKET: BY SOURCE 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Source
• 7.2. Human Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Humanized Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Chimeric Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.5. Other Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL ANTIBODY THERAPEUTICS MARKET: BY END USER 2022-2034 (USD MN)

• 8.1. Market Analysis, Insights and Forecast End User
• 8.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.3. Long-Term Care Facilities Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.4. Other Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 9. GLOBAL ANTIBODY THERAPEUTICS MARKET: BY REGION 2022-2034(USD MN)

• 9.1. Regional Outlook
• 9.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.2.1 By Format
  • 9.2.2 By Disease Areas
  • 9.2.3 By Route Of Administration
  • 9.2.4 By Source
  • 9.2.5 By End User
  • 9.2.6 United States
  • 9.2.7 Canada
  • 9.2.8 Mexico
• 9.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.3.1 By Format
  • 9.3.2 By Disease Areas
  • 9.3.3 By Route Of Administration
  • 9.3.4 By Source
  • 9.3.5 By End User
  • 9.3.6 United Kingdom
  • 9.3.7 France
  • 9.3.8 Germany
  • 9.3.9 Italy
  • 9.3.10 Russia
  • 9.3.11 Rest Of Europe
• 9.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.4.1 By Format
  • 9.4.2 By Disease Areas
  • 9.4.3 By Route Of Administration
  • 9.4.4 By Source
  • 9.4.5 By End User
  • 9.4.6 India
  • 9.4.7 Japan
  • 9.4.8 South Korea
  • 9.4.9 Australia
  • 9.4.10 South East Asia
  • 9.4.11 Rest Of Asia Pacific
• 9.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.5.1 By Format
  • 9.5.2 By Disease Areas
  • 9.5.3 By Route Of Administration
  • 9.5.4 By Source
  • 9.5.5 By End User
  • 9.5.6 Brazil
  • 9.5.7 Argentina
  • 9.5.8 Peru
  • 9.5.9 Chile
  • 9.5.10 South East Asia
  • 9.5.11 Rest of Latin America
• 9.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.6.1 By Format
  • 9.6.2 By Disease Areas
  • 9.6.3 By Route Of Administration
  • 9.6.4 By Source
  • 9.6.5 By End User
  • 9.6.6 Saudi Arabia
  • 9.6.7 UAE
  • 9.6.8 Israel
  • 9.6.9 South Africa
  • 9.6.10 Rest of the Middle East And Africa

Chapter 10. COMPETITIVE LANDSCAPE

• 10.1. Recent Developments
• 10.2. Company Categorization
• 10.3. Supply Chain & Channel Partners (based on availability)
• 10.4. Market Share & Positioning Analysis (based on availability)
• 10.5. Vendor Landscape (based on availability)
• 10.6. Strategy Mapping

Chapter 11. COMPANY PROFILES OF GLOBAL ANTIBODY THERAPEUTICS INDUSTRY

• 11.1. Top Companies Market Share Analysis
• 11.2. Company Profiles
  • 11.2.1 F. Hoffmann-La Roche Ltd. (Switzerland)
  • 11.2.2 AbbVie Inc. (US)
  • 11.2.3 Johnson & Johnson (US)
  • 11.2.4 Merck KGaA (Germany)
  • 11.2.5 Bristol-Myers Squibb (US)
  • 11.2.6 AstraZeneca (UK)
  • 11.2.7 Sanofi (France)
  • 11.2.8 Regeneron Pharmaceuticals, Inc. (US)
  • 11.2.9 Novartis AG (Switzerland)
  • 11.2.10 Amgen, Inc. (US)
  • 11.2.11 Biogen Inc. (US)